Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) chairman and CEO Armando Anido tells Proactive's Stephen Gunnion that the company has expanded its intellectual property (IP) portfolio for Zygel, the first and only pharmaceutically-manufactured cannabidiol formulated as a permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally.
Following a new US patent for the treatment of Fragile X Syndrome, Anido says Zynerba has now also received a patent for the treatment of 22q11.2 deletion syndrome (22q).
The next steps are to file for a New Drug Application for Fragile X, while it meets the Food and Drug Administration's suggestions to get regulatory approval for 22q, he adds.